
|Videos|January 9, 2018
Dr. Graff Discusses the Treatment of Prostate Cancer
Author(s)Julie Graff, MD
Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.
Advertisement
Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.
Currently there is one FDA-approved immunotherapy, sipuleucel-T (Provenge). There are other vaccines in development, as well as trials of checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, Graff adds.
In the next 5 to 10 years, Graff predicts that results from these studies will create more options for the treatment of patients with prostate cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































